Mozavaptan: Difference between revisions
Appearance
Content deleted Content added
حسن علي البط (talk | contribs) m Adding category Category:Benzazepines (using HotCat) |
added chemspider Id and InChI to drugbox |
||
Line 8: | Line 8: | ||
| ATC_supplemental = |
| ATC_supplemental = |
||
| PubChem = 119369 |
| PubChem = 119369 |
||
| ChemSpiderID = 106618 |
|||
| InChI = InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31) |
|||
| DrugBank = |
| DrugBank = |
||
| chemical_formula = |
| chemical_formula = |
Revision as of 11:33, 27 November 2010
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H29N3O2 |
Molar mass | 427.53 g/mol g·mol−1 |
3D model (JSmol) | |
|
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
References
- H. Spreitzer (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
- Prous Science: Molecule of the Month November 2006